MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation

Journal of Cell Science

Volumn 123, Issue 14, 2010, Pages 2423-2433

  Galli, Francesco ^a   Rossi, Mariangela ^b   D'Alessandra, Yuri ^a   De Simone, Marco ^a   Lopardo, Teresa ^a   Haupt, Ygal ^c   Alsheich Bartok, Osnat ^d   Anzi, Shira ^d   Shaulian, Eitan ^d   Calabrò, Viola ^b   La Mantia, Girolama ^b   Guerrini, Luisa ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d HEBREW UNIVERSITY   (Israel)

Author keywords

DNA damage; Fbw7; MDM2; p63

Indexed keywords

ACTIN; GLYCOGEN SYNTHASE KINASE 3; PROTEIN FBW7; PROTEIN MDM2; PROTEIN P63; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; ENZYME ACTIVITY; GENE DELETION; HUMAN; HUMAN CELL; KERATINOCYTE; NUCLEAR LOCALIZATION SIGNAL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RADIATION EXPOSURE; REGULATORY MECHANISM; ULTRAVIOLET IRRADIATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DNA DAMAGE; DOXORUBICIN; F-BOX PROTEINS; HUMANS; MICE; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; ULTRAVIOLET RAYS;

EID: 77954894921     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.061010     Document Type: Article

References (51)

1. Akhoondi, S., Sun, D., von der Lehr, N., Apostolidou, S., Klotz, K., Maljukova, A., Cepeda, D., Fiegl, H., Dafou, D., Marth, C. et al. (2007). FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67, 9006-9012.
2. Anzi, S., Finkin, S. and Shaulian, E. (2008). Transcriptional repression of c-Jun's E3 ubiquitin ligases contributes to c-Jun induction by UV. Cell Signal. 20, 862-871.
3. Calabrò, V., Mansueto, G., Parisi, T., Vivo, M., Calogero, R. A. and La Mantia, G. (2002). The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J. Biol. Chem. 277, 2674-2681. (Pubitemid 34953294)
4. Carter, S., Bischof, O., Dejean, A. and Vousden, K. H. (2007). C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9, 428-435. (Pubitemid 46511076)
5. Clegg, H. V., Itahana, K. and Zhang, Y. (2008). Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle 7, 87-92.
6. Crook, T., Nicholls, J. M., Brooks, L., O'Nions, J. and Allday, M. J. (2000). High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?. Oncogene 19, 3439-3444. (Pubitemid 30479339)
7. Deyoung, M. P. and Ellisen, L. W. (2007). p63 and p73 in human cancer: defining the network. Oncogene 26, 5169-5183.
8. Di Costanzo, A., Festa, L., Duverger, O., Vivo, M., Guerrini, L., La Mantia, G., Morasso, M. I. and Calabrò, V. (2009). Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation. Cell Cycle 8, 1185-1195.
9. Dohn, M., Zhang, S. and Chen, X. (2001). p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20, 3193-3205. (Pubitemid 32553672)
10. Finkin, S., Aylon, Y., Anzi, S., Oren, M. and Shaulian, E. (2008). Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene 27, 4411-4421.
11. Finlan, L. E. and Hupp, T. R. (2007). p63: the phantom of the tumor suppressor. Cell Cycle 6, 1062-1071.
12. Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F. and Jacks, T. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363-373. (Pubitemid 40544653)
13. Fuchs, S. Y. (2005). Tumor suppressor activities of the Fbw7 E3 ubiquitin ligase receptor. Cancer Biol. Ther. 4, 506-508.
14. Ganguli, G., Abecassis, J. and Wasylyk, B. (2000). MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J. 19, 5135-5147.
15. Ghioni, P., Bolognese, F., Duijf, P. H., vanBokhoven, H., Mantovani, R., and Guerrini, L. (2002). Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol. Cell. Biol. 22, 8659-8668.
16. Ghioni, P., D'Alessandra, Y., Mansueto, G., Jaffray, E., Hay, R. T., La Mantia, G. and Guerrini, L. (2005). The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 4, 183-190. (Pubitemid 41038949)
17. Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S., Bhat, K. P., Godfrey, V. L., Evan, G. I. and Zhang, Y. (2007). Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12, 355-366.
18. Jin, Y., Lee, H., Zeng, S. X., Dai, M. S. and Lu, H. (2003). MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 22, 6365-6377. (Pubitemid 37522593)
19. Kadakia, M., Slader, C. and Berberich, S. J. (2001). Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol. 20, 321-330. (Pubitemid 32692435)
20. Kimura, T., Gotoh, M., Nakamura, Y. and Arakawa, H. (2003). hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94, 431-436. (Pubitemid 36790475)
21. Knuutila, S., Aalto, Y., Autio, K., Bjorkqvist, A. M., El-Rifai, W., Hemmer, S., Huhta, T., Kettunen, E., Kiuru-Kuhlefelt, S., Larramendy, M. L. et al. (1999). DNA copy number losses in human neoplasms. Am. J. Pathol. 155, 683-694. (Pubitemid 29426813)
22. Koster, M. I., Huntzinger, K. A. and Roop, D. R. (2002). Epidermal differentiation: transgenic/knockout mouse models reveal genes involved in stem cell fate decisions and commitment to differentiation. J. Investig. Dermatol. 7, 41-45.
23. Koster, M. I., Kim, S., Mills, A. A., DeMayo, F. J. and Roop, D. R. (2004). p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 18, 126-131.
24. Kruse, J. P. and Gu, W. (2009). Modes of p53 regulation. Cell 137, 609-622.
25. Laurikkala, J., Mikkola, M. L., James, M., Tummers, M., Mills, A. A. and Thesleff, I. (2006). p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 133, 1553-1556.
26. Li, Y., Peart, M. J. and Prives, C. (2009). Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation. Mol. Cell. Biol. 29, 3953-3963.
27. Little, N. A. and Jochemsen, A. G. (2001). Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 20, 4576-4580.
28. Louria-Hayon, I., Alsheich-Bartok, O., Levav-Cohen, Y., Silberman, I., Berger, M., Grossman, T., Matentzoglu, K., Jiang, Y. H., Muller, S., Scheffner, M. et al. (2009). E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ. 16, 1156-1166.
29. Mao, J. H., Perez-Losada, J., Wu, D., Delrosario, R., Tsunematsu, R., Nakayama, K. I., Brown, K., Bryson, S. and Balmain, A. (2004). Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432, 775-779.
30. Michael, D. and Oren, M. (2002). The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12, 53-59.
31. Mills, A. A., Zheng, B., Wang, X. J., Vogel, H., Roop, D. R. and Bradley, A. (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708-713.
32. Murray-Zmijewski, F., Lane, D. P. and Bourdon, J. C. (2006). p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 13, 962-972.
33. O'Keefe, K., Li, H. and Zhang, Y. (2003). Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol. Cell. Biol. 23, 6396-6405.
34. O'Neil, J., Grim, J., Strack, P., Rao, S., Tibbitts, D., Winter, C., Hardwick, J., Welcker, M., Meijerink, J. P., Pieters, R. et al. (2007). FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813-1824.
35. Papoutsaki, M., Moretti, F., Lanza, M., Marinari, B., Sartorelli, V., Guerrini, L., Chimenti, S., Levrero, M. and Costanzo, A. (2005). A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes. Oncogene 24, 6970-6975.
36. Petitjean, A., Hainaut, P. and Caron de Fromentel, C. (2006). TP63 gene in stress response and carcinogenesis: a broader role than expected. Bull. Cancer 1, 126-135.
37. Punga, T., Bengoechea-Alonso, M. T. and Ericsson, J. (2006). Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J. Biol. Chem. 281, 25278-25286. (Pubitemid 44401915)
38. Ratovitski, E. A., Patturajan, M., Hibi, K., Trink, B., Yamaguchi, K. and Sidransky, D. (2001). p53 associates with and targets DeltaNp63 into a protein degradation pathway. Proc. Natl. Acad. Sci. USA 98, 1817-1822. (Pubitemid 32165581)
39. Rossi, M., Aqeilan, R. I., Neale, M., Candi, E., Salomoni, P., Knight, R. A., Croce, C. M. and Melino, G. (2006a). The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc. Natl. Acad. Sci. USA 103, 12753-12758. (Pubitemid 44298633)
40. Rossi, M., De Simone, M., Pollice, A., Santoro, R., La, Mantia, G., Guerrini, L. and Calabrò, V. (2006b). Itch/AIP4 associates with and promotes p63 protein degradation. Cell Cycle 5, 1816-1822. (Pubitemid 44435325)
41. Sdek, P., Ying, H., Chang, D. L., Qiu, W., Zheng, H., Touitou, R., Allday, M. J. and Xiao, Z. X. (2005). MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 20, 699-700.
42. Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K. and Nevins, J. R. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514.
43. Tan, Y., Sangfelt, O. and Spruck, C. (2008). The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett. 271, 1-12.
44. Thurfjell, N., Coates, P. J., Uusitalo, T., Mahani, D., Dabelsteen, E., Dahlqvist, A., Sjöström, B., Roos, G. and Nylander, K. (2004). Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int. J. Oncol. 25, 27-35.
45. Van Bokhoven, H. and Brunner, H. G. (2002). Splitting p63. Am. J. Hum. Genet. 71, 1-13.
46. Vousden, K. H. and Lane, D. P. (2007). p53 in health and disease. Nat. Rev. Mol. Cell. Biol. 8, 275-283.
47. Watson, I. R. and Irwin, M. S. (2006). Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8, 655-666.
48. Wei, W., Jin, J., Schlisio, S., Harper, J. W. and Kaelin, W. G. (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33. (Pubitemid 40991812)
49. Welcker, M. and Clurman, B. E. (2008). FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83-93. (Pubitemid 351161321)
50. Welcker, M., Singer, J., Loeb, K. R., Grim, J., Bloecher, A., Gurien-West, M., Clurman, B. E. and Roberts, J. M. (2003). Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 12, 381-392.
51. Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C. and McKeon, F. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714-718.